NEW YORK, June 23 - Inpharmatica said today that it plans to acquire certain assets relating to ADME (absorption, distribution, metabolism, and excretion) research from ArQule.
Specifically, Inpharmatica will take over ArQule's 10,000-square-foot Cambridge, UK, laboratories and will license some of the company's intellectual property. Fifteen of ArQule's Cambridge-based research staff will join Inpharmatica following the deal, which is subject to certain third party consents and agreements.
Financial terms of the acquisition were not disclosed.
Inpharmatica said it plans to use the newly acquired technology to enhance its PharmaCarta chemogenomics technology platform and to advance its internal discovery programs to the pre-clinical phase.